Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia

Kalir, Tamara; Wang, Beverly Y.; Goldfischer, Michael; Haber, Richard S.; Reder, Ilan; Demopoulos, Rita I.; Cohen, Carmel J.; Burstein, David

doi:10.1002/cncr.10280.abs

Cited by 33 publications

(53 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glut1 is a transmembrane protein that mediates facilitative transport of glucose (21). Its expression has been reported in various normal and neoplastic conditions as well as in the erythrocyte membrane (21,22). In normal peripheral nerves, Glut1 is expressed by perineurial cells (4,23).…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Demonstration of EMA/Glut1-Positive Perineurial Cells and CD34-Positive Fibroblastic Cells in Peripheral Nerve Sheath Tumors

et al. 2003

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Demonstration of EMA/Glut1-Positive Perineurial Cells and CD34-Positive Fibroblastic Cells in Peripheral Nerve Sheath Tumors

et al. 2003

View full text Add to dashboard Cite

“…GLUT1 also maintains a basal level of glucose uptake in most cell types under hypoxic and hypoglycemic conditions. The overexpression of GLUT1 has been observed in many types of human malignancies (7,8). In non-small cell lung cancers (NSCLC), the overexpression of GLUT1 is reportedly associated with a poor prognosis (9,10).…”

Section: Introductionmentioning

confidence: 99%

“…Tumor cells were considered positive for GLUT1 if the cell membrane staining was no less than that of the erythrocytes in the same section. GLUT1 expression was considered positive in each section if the percentage of tumor cells with positive staining was >10%, as previously reported (7,26,27). Ki-67 staining was evaluated using the labeling index (28,29).…”

Section: Introductionmentioning

confidence: 99%

Impact of GLUT1 and Ki-67 expression on early-stage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification

et al. 2012

View full text Add to dashboard Cite

Abstract. High expression levels of glucose transporter isoform 1 (GLUT1) and Ki-67 are reportedly associated with malignancy-related clinicopathological factors in malignant tumors. Recently, a new histological IASLC/ATS/ERS classification for lung adenocarcinoma was proposed. In this study, we investigated the clinicopathological impact of GLUT1 and Ki-67 expression on early-stage lung adenocarcinoma classified according to the IASLC/ATS/ERS classification. One hundred and five patients with completely resected stage IA lung adenocarcinoma were retrospectively classified into two groups, a ʻnon-invasive typeʼ (n=31) or an ʻinvasive typeʼ (n=74), based on the IASLC/ATS/ERS classification. GLUT1 and Ki-67 expression status was evaluated using immunohistochemistry. The epidermal growth factor receptor (EGFR) and KRAS mutation status was determined using PCR-based assays. Positive GLUT1 and Ki-67 expression and EGFR and KRAS mutations were detected in 28 (27%), 33 (31%), 51 (49%) and 5 (8%) cases, respectively. Positive GLUT1 expression was significantly associated with a wildtype EGFR and mutant KRAS status. A multivariate analysis revealed that positive GLUT1 expression was independently associated with the ʻinvasive typeʼ. In multivariate analyses for overall survival (OS) and disease-free survival (DFS), positive Ki-67 and GLUT1 expression was the only independent factor for a poor OS (P=0.012) and DFS (P=0.040), respectively. In addition, when stratified according to the GLUT1 and Ki-67 status, double-positive cases had the poorest DFS and OS times, compared with the other categories. Positive GLUT1 expression is associated with the invasive character of earlystage lung adenocarcinoma and with early disease relapse. Our results strongly suggest that GLUT1 and Ki-67 play important roles in acquiring biological malignant potential in early-stage lung adenocarcinoma.

show abstract

“…37 Malignant cells usually survive in the hypoxic microenvironment of the tumor with an increased glucose transport, in which the expression of glucose transporter-1 (GLUT-1) is reportedly upregulated. [38][39][40][41][42] GLUT-1 has been demonstrated to be overexpressed in pancreatic cancer, which promotes pancreatic cancer invasion and metastatic potential with activation and upregulation of matrix metalloproteinase-2 (MMP-2). Although, after the transfection with a vector encoding GLUT-1 siRNA which stably silenced the expression of GLUT-1, no significant changes were found in cell viability or proliferation in pancreatic cancer cell lines; whereas, the knockdown of GLUT-1 absolutely inhibited liver metastasis in vivo in the nude mice models, in which the downregulation of MMP-2 induced by silencing GLUT-1 might account for the antimetastasis.…”

Section: Rrm2mentioning

confidence: 99%

RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research

Chang

2007

Cancer Gene Ther

View full text Add to dashboard Cite

Pancreatic cancer is one of the most aggressive malignancies with a very poor prognosis, partially due to its very low accessibility to resection and resistance to chemoradiotherapy. As such, it is reasonable to find more effective, specific therapies and the related therapeutic targets. The identification of certain genes contributing to the tumorigenesis and poor prognosis provides the specific targets for efficient silencing by RNA interference (RNAi). As a powerful tool to suppress gene expression in mammalian cells, RNAi can be directed against pancreatic cancer through various pathways, including the inhibition of overexpressed oncogenes, suppression of tumor growth, metastasis and enhancement of apoptosis. In combination with chemoradiotherapy agents, RNAi can also attenuate the chemoradiation resistance of pancreatic cancer. In addition, RNAi has been used to define the 'loss of function' of endogenous genes in pancreatic cancer. This review provides a brief introduction to recent developments of RNAi applications in pancreatic cancer studies and suggestions for further exploration. It substantially demonstrates that RNAi holds a promising therapeutic potential as a future treatment for pancreatic cancer.

show abstract

Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia

Cited by 33 publications

References 0 publications

Immunohistochemical Demonstration of EMA/Glut1-Positive Perineurial Cells and CD34-Positive Fibroblastic Cells in Peripheral Nerve Sheath Tumors

Immunohistochemical Demonstration of EMA/Glut1-Positive Perineurial Cells and CD34-Positive Fibroblastic Cells in Peripheral Nerve Sheath Tumors

Impact of GLUT1 and Ki-67 expression on early-stage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification

RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research

Contact Info

Product

Resources

About